Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of licochalcone A in preparation of anti-anaphylactoid drugs

A technology for licorice chalcone and allergic reactions, applied in the field of biomedicine, to reduce local and systemic allergy-like symptoms, improve symptoms, and reduce mast cell degranulation

Pending Publication Date: 2021-08-27
XI AN JIAOTONG UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The research results of the prior art show that licochalcone A has anti-inflammatory, anti-cancer, anti-tumor, antibacterial, in vivo metabolism, anti-malarial and anti-parasitic effects, but there is no research on its anti-anaphylaxis-related effects. to report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of licochalcone A in preparation of anti-anaphylactoid drugs
  • Application of licochalcone A in preparation of anti-anaphylactoid drugs
  • Application of licochalcone A in preparation of anti-anaphylactoid drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Licochalcone A inhibits SP-induced KU812 cell β-hexosaminidase release

[0029] 1. Experimental materials

[0030] SP (purchased from MCE Company), KU812 cells, RPMI1640 medium (containing penicillin 100 U / mL, streptomycin 0.1 mg / mL, 20% FBS), Tyrode's solution, licochalcone A (purchased from Baoji Chenguang Company) , 0.1MNa 2 CO 3 , 0.1M NaHCO 3 , β-hexosaminidase, 0.1M citric acid, 0.1M sodium citrate.

[0031] The SP (Substance P) used refers to the neuropeptide discovered by Von Euler and Gaddum in 1931, the sequence is Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH 2 , the molecular weight is 1340.

[0032] Further, the purity of SP is ≥97%.

[0033] The structural formula of the licochalcone A is as follows:

[0034]

[0035] 2. Experimental method

[0036] KU812 cells were seeded in 96-well plates (1×10 5 per well), and the culture medium was discarded by centrifugation. Licochalcone A solutions (concentrations of 0 μM, 12.5 μM, 25 μM and ...

Embodiment 2

[0040] Example 2 Licochalcone A inhibits mouse toe swelling and Evans blue exudation caused by SP

[0041] 1. Experimental materials

[0042] SP (purchased from MCE Company), 6-8 week-old male C57 mice (purchased from the Experimental Animal Center of Xi'an Jiaotong University), licochalcone A (purchased from Baoji Chenguang), 0.4% Evans blue solution, 3.5% hydrated Chloral solution, PBS solution, normal saline, acetone.

[0043] 2. Experimental method

[0044]The mice were divided into blank control group, positive control group and licochalcone A administration groups of various concentrations. Licochalcone A solutions of different concentrations (respectively 20 mg / kg, 40 mg / kg, 80 mg / kg) were prepared with 0.5% CMC-Na solution for intragastric administration. After 30 minutes, mice were anesthetized with 3.5% chloral hydrate solution, and 0.4% Evans blue solution was injected into the tail vein. The thickness of the left and right soles of the mice in each group was me...

Embodiment 3

[0047] Example 3 Licochalcone A inhibits the increase of serum TNF-α content in mice caused by SP

[0048] 1. Experimental materials

[0049] SP (purchased from MCE Company), 6-8 week-old male C57 mice (purchased from the Experimental Animal Center of Xi'an Jiaotong University), licochalcone A (purchased from Baoji Chenguang), mouse TNF-αELISA kit (purchased from Beijing Yiqiao).

[0050] 2. Experimental method

[0051] The mice were divided into blank control group, positive control group and licochalcone A administration groups of various concentrations. Licochalcone A solutions of different concentrations (respectively 20 mg / kg, 40 mg / kg, 80 mg / kg) were prepared with 0.5% CMC-Na solution for intragastric administration. After 30 minutes, 30 μg / mL SP solution was injected into the tail vein, and the blank control group was injected with an equal volume of normal saline. After 1 hour, blood was collected, centrifuged at 10,000 g for 10 minutes, and serum was collected.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of licochalcone A in preparation of an anti-anaphylactoid drug. KU812 cell degranulation, toe swelling degree, toe Evans blue exudation degree and serum TNF-alpha release amount are compared to evaluate a to-be-detected medicine group, a normal saline control group and a normal control group, so that the treatment effect of the medicine on anaphylactoid diseases is evaluated, and the invention determines that the licochalcone A can be used for preparing the anti-anaphylactoid drug. The licochalcone A can effectively relieve local and systemic anaphylactoid reaction symptoms of mice; and the licochalcone A can reduce mast cell degranulation, and remarkably improve symptoms caused by anaphylactoid.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of licochalcone A in the preparation of antiallergic drugs. Background technique [0002] Anaphylaxis is not an immune response, and its etiology and mechanism are completely different from anaphylaxis. In immunology, the adverse reaction caused by the combination of antigen (or hapten) into the sensitized body and its specific antibody again is called allergic reaction. Allergic reactions require repeated exposure to antigens. During the first exposure, the sensitization process is completed by causing lymphocytes in the body to produce specific IgE to the antigen; when the body is exposed to the antigen again, the antigen binds to the IgE on the surface of mast cells to cause an allergic reaction The occurrence is an immune response. The occurrence of hypersensitivity reactions does not require the sensitization process of contacting antigens i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/12A61P37/08A61P17/00A61P9/02
CPCA61K31/12A61P37/08A61P17/00A61P9/02
Inventor 王楠张永竟王珏胡时灵
Owner XI AN JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com